Vascularis pleiozinergizmus - Egy új fogalom?

Translated title of the contribution: Vascular pleiosynergism - A new concept?

Research output: Contribution to journalArticle

Abstract

The coexistence of cardiovascular risk factors augments exponentially the relative risk value. Similarly, the parallel treatment of these risks proves multiplicative effectiveness. However, members of given drug classes show different capacity due to their variant main and other effects. Nowadays, among favorable "side" effects the pleoitropic form is in the focus of interest. In drugs with antiatherosclerotic outline the lipid lowering statins and the anti hypertensive third generation calcium channel blocker amlodipin posses the widest pleiotropic profile. According to the newest molecular biological results both of them are able to enhance endothelial nitrogen-monoxid (NO) synthesis, to inhibit production of reactive oxide radicals and to reduce the migration and proliferation of smooth muscle cells, which mechanisms are independent from their main effects. Statins and amlodipin can increase the activity of eNOS by influencing the caveolin/eNOS complex. The presence of common targets in direct and indirect effects seems to be important in gaining greater efficacy. The valuable indirect therapeutical "cross reaction" can be delineated as pleiosynergism. The recent revisited results of ASCOT-LLA trial support in vitro observations. The difference in primary end points of atorvastatin/amlodipin versus atorvastatin/atenolol regimen against placebo was more than three times (3.3 x) greater in favour to amlodipin combination. The same benefits were seen in secondary end points. Because the capacity of the two schedules lowering blood pressure was very similar, the advantage can be based dominantly on the pleiosynergistic interaction between atorvastatin and amlodipin.

Original languageHungarian
Pages (from-to)1973-1976
Number of pages4
JournalOrvosi Hetilap
Volume147
Issue number41
Publication statusPublished - Oct 15 2006

Fingerprint

Blood Vessels
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Caveolins
Atenolol
Cross Reactions
Calcium Channel Blockers
Pharmaceutical Preparations
Oxides
Antihypertensive Agents
Smooth Muscle Myocytes
Appointments and Schedules
Nitrogen
Placebos
Blood Pressure
Lipids
Atorvastatin Calcium
Therapeutics
In Vitro Techniques

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Vascularis pleiozinergizmus - Egy új fogalom? / Császár, A.

In: Orvosi Hetilap, Vol. 147, No. 41, 15.10.2006, p. 1973-1976.

Research output: Contribution to journalArticle

Császár, A. / Vascularis pleiozinergizmus - Egy új fogalom?. In: Orvosi Hetilap. 2006 ; Vol. 147, No. 41. pp. 1973-1976.
@article{c2908b3f90a345609f9f48d210e4c20b,
title = "Vascularis pleiozinergizmus - Egy {\'u}j fogalom?",
abstract = "The coexistence of cardiovascular risk factors augments exponentially the relative risk value. Similarly, the parallel treatment of these risks proves multiplicative effectiveness. However, members of given drug classes show different capacity due to their variant main and other effects. Nowadays, among favorable {"}side{"} effects the pleoitropic form is in the focus of interest. In drugs with antiatherosclerotic outline the lipid lowering statins and the anti hypertensive third generation calcium channel blocker amlodipin posses the widest pleiotropic profile. According to the newest molecular biological results both of them are able to enhance endothelial nitrogen-monoxid (NO) synthesis, to inhibit production of reactive oxide radicals and to reduce the migration and proliferation of smooth muscle cells, which mechanisms are independent from their main effects. Statins and amlodipin can increase the activity of eNOS by influencing the caveolin/eNOS complex. The presence of common targets in direct and indirect effects seems to be important in gaining greater efficacy. The valuable indirect therapeutical {"}cross reaction{"} can be delineated as pleiosynergism. The recent revisited results of ASCOT-LLA trial support in vitro observations. The difference in primary end points of atorvastatin/amlodipin versus atorvastatin/atenolol regimen against placebo was more than three times (3.3 x) greater in favour to amlodipin combination. The same benefits were seen in secondary end points. Because the capacity of the two schedules lowering blood pressure was very similar, the advantage can be based dominantly on the pleiosynergistic interaction between atorvastatin and amlodipin.",
keywords = "Amlodipin, Pleiotropy, Statin, Synergism, Vascular effect",
author = "A. Cs{\'a}sz{\'a}r",
year = "2006",
month = "10",
day = "15",
language = "Hungarian",
volume = "147",
pages = "1973--1976",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "41",

}

TY - JOUR

T1 - Vascularis pleiozinergizmus - Egy új fogalom?

AU - Császár, A.

PY - 2006/10/15

Y1 - 2006/10/15

N2 - The coexistence of cardiovascular risk factors augments exponentially the relative risk value. Similarly, the parallel treatment of these risks proves multiplicative effectiveness. However, members of given drug classes show different capacity due to their variant main and other effects. Nowadays, among favorable "side" effects the pleoitropic form is in the focus of interest. In drugs with antiatherosclerotic outline the lipid lowering statins and the anti hypertensive third generation calcium channel blocker amlodipin posses the widest pleiotropic profile. According to the newest molecular biological results both of them are able to enhance endothelial nitrogen-monoxid (NO) synthesis, to inhibit production of reactive oxide radicals and to reduce the migration and proliferation of smooth muscle cells, which mechanisms are independent from their main effects. Statins and amlodipin can increase the activity of eNOS by influencing the caveolin/eNOS complex. The presence of common targets in direct and indirect effects seems to be important in gaining greater efficacy. The valuable indirect therapeutical "cross reaction" can be delineated as pleiosynergism. The recent revisited results of ASCOT-LLA trial support in vitro observations. The difference in primary end points of atorvastatin/amlodipin versus atorvastatin/atenolol regimen against placebo was more than three times (3.3 x) greater in favour to amlodipin combination. The same benefits were seen in secondary end points. Because the capacity of the two schedules lowering blood pressure was very similar, the advantage can be based dominantly on the pleiosynergistic interaction between atorvastatin and amlodipin.

AB - The coexistence of cardiovascular risk factors augments exponentially the relative risk value. Similarly, the parallel treatment of these risks proves multiplicative effectiveness. However, members of given drug classes show different capacity due to their variant main and other effects. Nowadays, among favorable "side" effects the pleoitropic form is in the focus of interest. In drugs with antiatherosclerotic outline the lipid lowering statins and the anti hypertensive third generation calcium channel blocker amlodipin posses the widest pleiotropic profile. According to the newest molecular biological results both of them are able to enhance endothelial nitrogen-monoxid (NO) synthesis, to inhibit production of reactive oxide radicals and to reduce the migration and proliferation of smooth muscle cells, which mechanisms are independent from their main effects. Statins and amlodipin can increase the activity of eNOS by influencing the caveolin/eNOS complex. The presence of common targets in direct and indirect effects seems to be important in gaining greater efficacy. The valuable indirect therapeutical "cross reaction" can be delineated as pleiosynergism. The recent revisited results of ASCOT-LLA trial support in vitro observations. The difference in primary end points of atorvastatin/amlodipin versus atorvastatin/atenolol regimen against placebo was more than three times (3.3 x) greater in favour to amlodipin combination. The same benefits were seen in secondary end points. Because the capacity of the two schedules lowering blood pressure was very similar, the advantage can be based dominantly on the pleiosynergistic interaction between atorvastatin and amlodipin.

KW - Amlodipin

KW - Pleiotropy

KW - Statin

KW - Synergism

KW - Vascular effect

UR - http://www.scopus.com/inward/record.url?scp=34748879374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34748879374&partnerID=8YFLogxK

M3 - Article

VL - 147

SP - 1973

EP - 1976

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 41

ER -